- Home
- SNTI vs DTIL Comparison
SNTI vs DTIL Comparison
Compare SNTI & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- DTIL
- Stock Information
- Founded
- SNTI 2016
- DTIL 2006
- Country
- SNTI United States
- DTIL United States
- Employees
- SNTI N/A
- DTIL N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- DTIL Health Care
- Exchange
- SNTI Nasdaq
- DTIL Nasdaq
- Market Cap
- SNTI 50.3M
- DTIL 51.6M
- IPO Year
- SNTI N/A
- DTIL 2019
- Fundamental
- Price
- SNTI $1.70
- DTIL $4.75
- Analyst Decision
- SNTI Strong Buy
- DTIL Strong Buy
- Analyst Count
- SNTI 2
- DTIL 2
- Target Price
- SNTI $8.50
- DTIL $47.00
- AVG Volume (30 Days)
- SNTI 511.1K
- DTIL 217.8K
- Earning Date
- SNTI 08-12-2025
- DTIL 08-12-2025
- Dividend Yield
- SNTI N/A
- DTIL N/A
- EPS Growth
- SNTI N/A
- DTIL N/A
- EPS
- SNTI N/A
- DTIL N/A
- Revenue
- SNTI N/A
- DTIL $51,141,000.00
- Revenue This Year
- SNTI N/A
- DTIL N/A
- Revenue Next Year
- SNTI $150.00
- DTIL $53.21
- P/E Ratio
- SNTI N/A
- DTIL N/A
- Revenue Growth
- SNTI N/A
- DTIL N/A
- 52 Week Low
- SNTI $1.52
- DTIL $3.61
- 52 Week High
- SNTI $16.94
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- SNTI 29.96
- DTIL 49.86
- Support Level
- SNTI $1.86
- DTIL $4.51
- Resistance Level
- SNTI $2.12
- DTIL $5.12
- Average True Range (ATR)
- SNTI 0.15
- DTIL 0.32
- MACD
- SNTI 0.00
- DTIL 0.03
- Stochastic Oscillator
- SNTI 0.00
- DTIL 48.98
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.